Download Files:
Glenzocimab
Price range: 365 CAD through 3,168 CAD
Products Details
Product Description
– Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Web ID
– T77442
Storage Temperature
– -20℃
Shipping
– Blue Ice
References
– Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513.
CAS Number
– 2101829-58-5
Molecular Weight
Compound Purity
– 100% (SEC-HPLC)
Pathway
– Others
Product type
– Inhibitory Antibodies
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
